Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, February 18, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, February 17, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, February 16, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Paul Matteis Maintained (ALNY) at Buy with Decreased Target to $120 on, Feb 16th, 2016
Paul Matteis of Leerink Swann, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Buy with Decreased Target from $152 to $120 on, Feb 16th, 2016.
Paul has made no other calls on ALNY in the last 4 months.
There is 1 other peer that has a rating on ALNY. Out of the 1 peers that are also analyzing ALNY, 0 agree with Paul's Rating of Hold.
This is the rating of the analyst that currently disagrees with Paul
- Alethia Young of "Credit Suisse" Initiated at Buy and Held Target at $154 on, Wednesday, January 20th, 2016
